Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
- Status
- COMPLETED
- Phase
- PHASE3
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
- Status
- UNKNOWN
- Phase
- N/A
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
- Status
- WITHDRAWN
- Phase
- PHASE2
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
- Status
- RECRUITING
- Phase
- PHASE2
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE3
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
- Status
- UNKNOWN
- Phase
- N/A
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
- Status
- COMPLETED
- Phase
- PHASE2
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2